Integra LifeSciences Holdings Co. (NASDAQ:IART) Position Decreased by Dimensional Fund Advisors LP

Dimensional Fund Advisors LP decreased its holdings in shares of Integra LifeSciences Holdings Co. (NASDAQ:IART – Get Rating) by 5.6% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,203,527 shares of the life sciences company’s stock after selling 71,407 shares during the period. Dimensional Fund Advisors LP owned approximately 1.44% of Integra LifeSciences worth $67,485,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. South Dakota Investment Council boosted its holdings in shares of Integra LifeSciences by 36.0% in the fourth quarter. South Dakota Investment Council now owns 34,396 shares of the life sciences company’s stock worth $1,929,000 after buying an additional 9,100 shares during the period. Teza Capital Management LLC boosted its holdings in shares of Integra LifeSciences by 9.7% in the third quarter. Teza Capital Management LLC now owns 8,114 shares of the life sciences company’s stock worth $344,000 after buying an additional 716 shares during the period. Teacher Retirement System of Texas boosted its holdings in shares of Integra LifeSciences by 243.4% in the third quarter. Teacher Retirement System of Texas now owns 40,989 shares of the life sciences company’s stock worth $1,736,000 after buying an additional 29,054 shares during the period. NorthCrest Asset Manangement LLC boosted its holdings in shares of Integra LifeSciences by 2.8% in the fourth quarter. NorthCrest Asset Manangement LLC now owns 14,180 shares of the life sciences company’s stock worth $795,000 after buying an additional 380 shares during the period. Finally, Retirement Systems of Alabama boosted its holdings in shares of Integra LifeSciences by 1.0% in the third quarter. Retirement Systems of Alabama now owns 95,110 shares of the life sciences company’s stock worth $4,029,000 after buying an additional 926 shares during the period. 87.60% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

IART has been the subject of several recent analyst reports. Citigroup cut shares of Integra LifeSciences from a “neutral” rating to a “sell” rating and decreased their target price for the stock from $59.00 to $39.00 in a report on Tuesday. JMP Securities reduced their price target on shares of Integra LifeSciences from $75.00 to $65.00 in a research report on Thursday, April 27th. Truist Financial reduced their price target on shares of Integra LifeSciences from $58.00 to $54.00 in a research report on Thursday, May 18th. JPMorgan Chase & Co. lowered shares of Integra LifeSciences from a “neutral” rating to an “underweight” rating and reduced their price target for the stock from $56.00 to $43.00 in a research report on Wednesday. Finally, StockNews.com initiated coverage on shares of Integra LifeSciences in a research report on Thursday, May 18th. They issued a “buy” rating for the company. Two research analysts have rated the stock with a sell rating, three have given a hold rating and two have assigned a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $51.14.

Insider Activity at Integra LifeSciences

In related news, EVP Michael J. Mcbreen sold 1,843 shares of the firm’s stock in a transaction that occurred on Tuesday, March 7th. The shares were sold at an average price of $54.29, for a total transaction of $100,056.47. Following the transaction, the executive vice president now owns 28,796 shares of the company’s stock, valued at $1,563,334.84. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. In other news, EVP Michael J. Mcbreen sold 1,843 shares of Integra LifeSciences stock in a transaction that occurred on Tuesday, March 7th. The shares were sold at an average price of $54.29, for a total value of $100,056.47. Following the transaction, the executive vice president now owns 28,796 shares of the company’s stock, valued at $1,563,334.84. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, EVP Lisa Evoli sold 3,767 shares of Integra LifeSciences stock in a transaction that occurred on Monday, February 27th. The shares were sold at an average price of $57.00, for a total transaction of $214,719.00. Following the completion of the transaction, the executive vice president now directly owns 18,605 shares in the company, valued at approximately $1,060,485. The disclosure for this sale can be found here. Insiders own 4.20% of the company’s stock.

Integra LifeSciences Price Performance

Shares of IART opened at $38.48 on Friday. The firm has a market cap of $3.15 billion, a PE ratio of 18.68, a PEG ratio of 1.19 and a beta of 1.15. The firm’s 50 day moving average price is $53.62 and its 200 day moving average price is $55.03. The company has a debt-to-equity ratio of 0.86, a quick ratio of 2.40 and a current ratio of 3.65. Integra LifeSciences Holdings Co. has a twelve month low of $38.13 and a twelve month high of $62.99.

Integra LifeSciences (NASDAQ:IART – Get Rating) last issued its quarterly earnings data on Wednesday, April 26th. The life sciences company reported $0.74 earnings per share for the quarter, meeting the consensus estimate of $0.74. The firm had revenue of $380.85 million for the quarter, compared to analyst estimates of $373.21 million. Integra LifeSciences had a net margin of 11.00% and a return on equity of 16.29%. The company’s revenue for the quarter was up 1.1% on a year-over-year basis. During the same quarter last year, the firm earned $0.74 earnings per share. As a group, research analysts expect that Integra LifeSciences Holdings Co. will post 3.42 EPS for the current fiscal year.

Integra LifeSciences Company Profile

(Get Rating)

Integra LifeSciences Holdings Corp. engages in the provision of regenerative tissue technologies and neurological solutions dedicated to limiting uncertainty for clinicians. It operates under the Codman Specialty Surgical (CSS) and Tissue Technologies (TT) segments. The CSS segment includes technologies and instrumentation used for neurosurgery, neurocritical care, and otolaryngology.